UNIVERSITY OF MICHIGAN

Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.

Courage Therapeutics has appointed biopharma veteran Giovanni Ferrara as CEO following a significant investment from Arsenal Bridge Ventures in May.

Epcoritamab-bysp achieved durable complete responses in patients with relapsed/refractory large B-cell lymphoma, with 96% of complete responders at 2 years maintaining remission at 3 years.

Mayo Clinic researchers identified that mineralocorticoid receptor proteins clump together during cold storage, causing cardiac damage through increased inflammation and cell death.

• University of Michigan researchers have demonstrated that DT-109, a glycine-based tripeptide, significantly reduces atherosclerotic plaque formation in nonhuman primates while inhibiting vascular calcification processes. • The compound, which previously showed efficacy in treating metabolic dysfunction-associated steatotic liver disease (MASH), represents a potential breakthrough as a dual-action therapy addressing both liver dysfunction and cardiovascular complications. • Unlike conventional treatments that primarily lower cholesterol, DT-109 targets underlying inflammatory pathways including NLRP3 inflammasome signaling, potentially addressing root causes of atherosclerosis rather than just managing symptoms.

Breakthrough T1D has awarded $2.8 million over three years to create the U-M-OHSU Cardiorenal Center of Excellence, expanding research on heart and kidney complications in type 1 diabetes patients.

The Trump administration has terminated 323 NIH grants worth $806 million focused on LGBTQ health research, affecting studies on HIV prevention, cancer, and mental health.

One-third of Americans aged 50-80 report feeling lonely, with rates returning to pre-pandemic levels after peaking at 42% during COVID-19, according to University of Michigan research.

Substance use among adolescents has maintained historically low levels for the fourth consecutive year following significant declines during the COVID-19 pandemic, according to the latest NIH-funded Monitoring the Future survey.

MyProstateScore 2.0, a genetics-based urine test, demonstrates 94% sensitivity in detecting aggressive prostate cancer without requiring a digital rectal examination.